Granulocyte colony-stimulating factor (G-CSF)-induced mobilization of circulating haemopoietic stem cells

Br J Haematol. 1993 Aug;84(4):570-3. doi: 10.1111/j.1365-2141.1993.tb03129.x.

Abstract

We studied the utility of G-CSF for harvesting circulating haematopoietic stem cells in patients with leukaemia or lymphoma based on a comparative study in a single patient. Two successive cycles of leukapheresis following cytotoxic chemotherapy were performed in 22 patients as follows: the first cycle was performed with cytotoxic mobilization in all patients while the second cycle was randomized into two groups: cytotoxic (n = 10) and cytotoxic plus G-CSF (cytotoxic/G-CSF) (n = 12) mobilization. Repetitive cytotoxic mobilization did not alter the yields of mononuclear cells (MNC), myeloid (CFU-GM), and erythroid (BFU-E) progenitors. In contrast, cytotoxic/G-CSF mobilization produced significantly higher yields of MNC (2.6-fold), CFU-GM (5.5-fold), and BFU-E (3.9-fold) than did cytotoxic mobilization alone (P < 0.01). The ratio of CFU-GM to BFU-E was not affected by G-CSF. Furthermore, G-CSF led to an earlier peak of CFU-GM following chemotherapy. G-CSF is thus effective in expanding the pool of circulating haematopoietic progenitors.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Child
  • Female
  • Granulocyte Colony-Stimulating Factor / pharmacology*
  • Hematopoietic Stem Cells / drug effects*
  • Humans
  • Leukapheresis
  • Leukemia / blood*
  • Leukemia / drug therapy
  • Lymphoma, Non-Hodgkin / blood*
  • Lymphoma, Non-Hodgkin / drug therapy
  • Male
  • Middle Aged

Substances

  • Granulocyte Colony-Stimulating Factor